|Home | About | Journals | Submit | Contact Us | Français|
Loss-of-function mutations in the SCN5A-encoded sodium channel SCN5A or Nav1.5 have been identified in idiopathic ventricular fibrillation (IVF) in the absence of Brugada syndrome phenotype. Nav1.5 is regulated by four sodium channel auxiliary β subunits. Here, we report a case with IVF and a novel mutation in the SCN3B-encoded sodium channel β subunit Navβ3 that causes a loss of function of Nav1.5 channels in vitro.
Comprehensive open reading frame mutational analysis of KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, GPD1L, four sodium channel β subunit genes (SCN1-4B), and targeted scan of RYR2 was performed. A novel missense mutation, Navβ3-V54G, was identified in a 20-year-old male following witnessed collapse and defibrillation from VF. The ECG exhibited epsilon waves, and imaging studies demonstrated a structurally normal heart. The mutated residue was highly conserved across species, localized to the Navβ3 extracellular domain, and absent in 800 reference alleles. We found that HEK-293 cells had endogenous Navβ3, but COS cells did not. Co-expression of Nav1.5 with Navβ3-V54G (with or without co-expression of the Navβ1 subunit) in both HEK-293 cells and COS cells revealed a significant decrease in peak sodium current and a positive shift of inactivation compared with WT. Co-immunoprecipitation experiments showed association of Navβ3 with Nav1.5, and immunocytochemistry demonstrated a dramatic decrease in trafficking to the plasma membrane when co-expressed with mutant Navβ3-V54G.
This study provides molecular and cellular evidence implicating mutations in Navβ3 as a cause of IVF.
Voltage-gated sodium channels play a fundamental role in many electrically excitable cells and tissues and more particularly in the contractile myocardium and specialized conduction tissue in the heart. Mutations causing loss of function of the Nav1.5 channel and decreasing peak sodium current (INa) are responsible for some forms of Brugada syndrome (BrS), idiopathic ventricular fibrillation (IVF), progressive cardiac conduction disease, autosomal recessive congenital sick sinus syndrome, atrial fibrillation, and dilated cardiomyopathy. IVF is characterized by spontaneous ventricular fibrillation in the absence of structural heart disease (coronary/valvular heart disease, myocarditis, cardiomyopathy) and in the absence of well-defined electrophysiological diseases such as LQTS, BrS, and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).1 Three IVF-susceptibility genes have now been implicated (SCN5A, dipeptidyl-aminopeptidase-like protein 6 (DPP6), and KCNJ8).2–4 The first to be described were loss-of-function mutations in SCN5A where an IVF phenotype was noted in the absence of BrS features.2 Recently, DPP6, which modulate transient outward current kinetics, was reported in a familial IVF pedigree.3 Also, a mutation in the KCNJ8-encoded pore-forming subunit, Kir6.1, of the ATP-sensitive potassium channel was recently reported in a young female with IVF,4 but the functional effects of this mutation were not investigated. Here, we report the initial human mutation in the SCN3B-encoded sodium channel Navβ3 subunit from a patient diagnosed clinically with IVF and show that it causes decreased INa as evidence for a plausible cause of the arrhythmia.
Comprehensive open reading frame/splice site mutational analysis of KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, SCN1B, SCN2B, SCN3B, SCN4B, and targeted RYR2 was performed using polymerase chain reaction (PCR), denaturing high-performance liquid chromatography (DHPLC), and direct DNA sequencing as described previously.5 The study was performed according to the terms required by the Mayo Foundation Institution Review Board and conforms to the Declaration of Helsinki. Written informed consent was obtained from all participants (IRB protocol 1216-97).
Navβ3 (GenBank Acc no. NM_018400) was cloned from human heart mRNA (Clontech, Palo Alto, CA, USA) with RT–PCR and two primers: 5-ATGCCTGCCTTCAATAGATTG-3 and 5-CTATTCCTCCACTGGTACC-3, then subcloned into the eukaryotic expression vectors pcDNA3 (Invitrogen, Carlsbad, CA, USA) and IRES-GFP, and confirmed by DNA sequencing analysis (Biotech Center of the University of Wisconsin-Madison). The cDNA of voltage-gated sodium channel alpha subunit gene, SCN5A (GenBank Acc. no. AY148488) was also subcloned into pcDNA3 vector (Invitrogen), and both were transiently transfected into in HEK-293 cells at 1 : 1 ratio using Fugene (Roche). The novel missense mutation, Navβ3-V54G, was engineered into the Navβ3-WT by site-directed mutagenesis using QuikChange site-directed mutagenesis kit (Stratagene). For co-immunoprecipitation (co-IP) experiments, the FLAG peptide of DYKDDDDK was incorporated into SCN5A at the extracellular linker of DI between S1-2 and confirmed by sequencing.
INa from HEK-293 or COS cells co-expressing SCN5A with WT- and/or Navβ3-V54G, and/or WT-Navβ1 or an empty vector were recorded using the whole-cell configuration of the patch clamp technique using an Axopatch 200B amplifier and pClamp8.0 and data were acquired and analysed using software (Axon Instruments, Foster City, CA, USA) as described previously.6 INa was normalized to cell capacity and reported as pA/pF. The electrophysiological recordings were carried out at room temperature. The bath (extracellular) solution contained (in mM): NaCl 140, KCl 4, CaCl2 1.8, MgCl2 0.75, HEPES 5 (pH 7.4 set with NaOH). The pipette (intracellular) solution contained: CsF 120, CsCl 20, EGTA 2, HEPES 5 (pH 7.4 set with CsOH).
A rabbit polyclonal anti-Navβ3 antibody was generated against residues 65–83 of the Navβ3 (YenZym Antibodies, LLC, South San Francisco, CA, USA). Co-IP between SCN5A and Navβ3 was performed using mouse heart and cell lysates from HEK-293 cells co-expressing the SCN5A tagged with a Flag epitope and the Navβ3-WT or the Navβ3-V54G. HEK-293 cells were lysed in RIPA buffer (25 mM Tris–HCl at pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 1 mM DTT) containing complete protease inhibitor cocktail (Roche, Basel, Switzerland). The preparation was immunoprecipitated with 1 µg of Navβ3 rabbit antibody (Zymed laboratories) or anti-Flag antibody (Sigma-Aldrich), and then electrophoretically separated by 4–20% SDS–PAGE and transferred into PVDF membranes for immunoblotting with either of the following antibodies: Nav1.5 antibody (Upstate Laboratory), anti-Flag-M2 antibody (Sigma), or anti-Navβ3 antibody. Complexes were developed using the ECL-plus kit (Amersham Biosciences).
HEK-293 cells were transfected with SCN5A and the WT or Navβ3-V54G and after 24 h, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton, and quenched with glycine. The cells were then blocked for 30 min with buffer (10% goat serum and 5 mM NaN3–PBS) and incubated with the primary antibodies mouse anti-Flag-M2 (Sigma) against the Flag-tagged SCN5A and rabbit anti-Navβ3 for 1 h at 37°C at 1 : 1000 dilution The cells were washed three times for 10 min with washing buffer and incubated with secondary antibodies: Alexa 488 and Alexa 568 anti-mouse and anti-rabbit, respectively (Molecular Probes, Eugene, OR, USA) for 30 min at 37°C at 1 : 500 dilution, then washed three times for 10 min. The fluorescent labelled HEK-293 cells were viewed using a confocal imaging system FLUOVIEW 1000 mounted on an inverted microscope (Olympus). A 60× oil-immersion lens with a Kalman collection filter with two frames per image was used to record images. Z series were created by sequential scanning of green and red at 0.5 mm steps.
COS cells expressing only empty vector or co-expressing SCN5A and Navβ3-WT or Navβ3-V54G were plated into collagen-coated 35 mm tissue culture plates and cultured overnight. For imaging, the cell culture media (MEM with 10% foetal bovine serum) was supplemented for 1 h with a primary anti-Flag antibody (1 : 500) at 37°C. The cells were washed for 10 min three times with cell culture media at 37°C. The cells were then cultured for 1 h in the secondary antibody IRDye 800 goat anti-mouse (1 : 500) (Li-cor Biosciences, Lincoln, NE, USA) at 37°C. Cells were then washed once in PBS for 10 min. The cells were imaged using the Li-cor Odyssey infrared imaging system (Li-cor Biosciences) and the intensity of the 800 nm infrared signal for each well was quantified using the Li-cor Odyssey infrared imaging system software. The mean intensity of a plate that contain untransfected cells was subtracted from the intensity of plates with cells expressing SCN5A + vector, SCN5A + Navβ3-WT, SCN5A + Navβ3-V54G, or SCN5A + both Navβ3-WT and -V54G (1 : 1) to correct for any background signal not related to Flag staining.
Summary data are shown as the mean ± standard error of the mean. Statistical significance was determined by using a Student's t-test for comparisons of two means or, when appropriate, analysis of variance (ANOVA) for comparisons of multiple means. A P-value of <0.05 was considered statistically significant.
In 2001, a 20-year-old otherwise healthy male suddenly lost consciousness while playing basketball as his sentinel cardiac event. The emergency response team found him in ventricular fibrillation, and he was defibrillated rapidly and successfully on the basketball court and recovered fully with no neurological sequelae. He had no prior syncopal spells, and there was no history of sudden death in his family. After comprehensive cardiological evaluation both locally and after referral to Mayo Clinic, the only peculiarity noted was an epsilon wave on 12-lead ECG (Figure 1). However, the T waves were not inverted in the right precordial leads, and there was no other evidence to suggest ARVC/D. Specifically, there was no ectopy on ambulatory recording or late potentials on signal-averaged ECG, and the echocardiogram was normal with no structural cardiac disease. In addition, a cardiac CT scan with and without contrast was unremarkable with no fatty infiltration of the right ventricle, aneurysmal dilatation, right ventricular enlargement, or dysfunction noted. With these negative findings, a right ventricular biopsy for AVRC was considered to be low yield for the risk. Besides ARVC/D and other cardiomyopathies, other possible cardiac conditions (anomalous coronary arteries, long QT syndrome, BrS, and catecholaminergic polymorphic ventricular tachycardia) were evaluated and excluded by a negative coronary angiogram, negative epinephrine QT stress test, negative procainamide challenge, and negative electrophysiology study with and without isoproterenol. An ICD was implanted without complication. The patient returned for follow-up 1 year later for repeat imaging studies and once again the contrast CT scan was unremarkable. No subsequent events have occurred after 8 years of follow-up.
Twelve-lead ECG of the 20-year-old index case showing sinus rhythm, QRS axis within normal limits. Epsilon waves are evident in leads V1, V2, and V3.
Mutational analysis of the RYR2 and LQTS genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) did not yield putative arrhythmia mutations. A T to G base substitution at position 161 was identified in SCN3B which yielded a missense mutation V54G [valine (V) to glycine (G) at position 54] (Figure 2A). This mutation was absent in 800 references alleles. V54G was localized to the extracellular region of the Navβ3 subunit and involves a highly conserved residue across species (Figure 2B and D). The proband's mother hosted the mutation and was asymptomatic, but notably also displayed ‘J’ point elevation on his 12-lead ECG (Figure 2C).
(A) Left: Proband DNA sequence chromatogram showing a T > G substitution generating a valine (V) to glycine (G) substitution at residue 54 of Navβ3. Right: Wild-type DHPLC profile in blue colour, mutant, and aberrant profile in red colour. ...
Representative INa traces from HEK-293 cells expressing SCN5A co-expressed with a blank vector control, Navβ3-WT, or Navβ3-V54G (Figure 3A) show that the mutation markedly decreased peak INa density, and summary data (Figure 3B) show that this decrease was statistically significant. Summary plots of the current–voltage relationship normalized to peak (Figure 4A and Table 1) show that Navβ3-V54G caused a depolarizing shift of the voltage dependence of activation compared with Navβ3-WT, but not to SCN5A + vector; this effect may have contributed to the decreased INa density. In HEK-293 cells, but not COS cells, Navβ3-WT caused a 4 mV negative shift in the midpoint of inactivation compared with SCN5A + vector, and this effect was lost in the presence of Navβ3-V54G (Figure 4B and Table 1). These data are consistent with changes in kinetics that result in a ‘loss of function’ by Navβ3-V54G. No changes were observed for late persistent INa (Table 1).
Navβ3-V54G reduced INa in HEK-293 cells (A) Whole-cell current traces from representative cells expressing SCN5A + vector, SCN5A co-expressed with β3-WT or Navβ3-V54G 24 h after transfection. INa was elicited from a step depolarization ...
Navβ3-WT shifted inactivation kinetics, but Navβ3-V54G did not. (A) Peak current–voltage plot of summary INa normalized to the maximal INa in response to a series of depolarizations from a holding potential of −140 mV. ...
Kinetics of SCN5A + β3 in HEK-293 cells
We developed a Navβ3 antibody with the epitope targeted to the extracellular domain of Navβ3. The antibody gave bands at the expected molecular weight for Navβ3-WT and Navβ3-V54G expressed in COS cells, but not for the Navβ1, Navβ2, or Navβ4 subunits of the sodium channel (data not shown), suggesting that the antibody was specific for the Navβ3 subunit over other highly homologous sodium channel β subunits. Interestingly, we detected a band for Navβ3 in non-transfected HEK-293 cells, the standard cell line used for studies of SCN5A, but not in COS cells (data not shown). To determine whether SCN5A and Navβ3 are associated, we performed co-IP experiments by immunoprecipitating with the Navβ3 antibody and probing for SCN5A with Nav1.5 antibody or anti-Flag antibody (Figure 5). In HEK-293 cells co-expressing SCN5A and Navβ3-WT (Figure 5A, lane 4), the Navβ3 subunit antibody co-immunoprecipitated SCN5A, and it also co-immunoprecipitated SCN5A when SCN5A was expressed alone (Figure 5A, lane 3), consistent with the finding that HEK-293 cells have endogenous Navβ3 subunits. SCN5A was also co-immunoprecipitated by Navβ3 in homogenates obtained from adult cardiac myocytes from mouse (Figure 5A, lane 1), but the signal for SCN5A in neonatal mouse myocytes was very weak, consistent with a reported absence of Navβ3 subunits at this stage.7 Co-expressing Navβ3-WT or Nav3-V54G and the Flag-tagged SCN5A in COS cells also co-immunoprecipitated the complex.
Co-IP of SCN5A and Navβ3 subunits. (A) Heart homogenates were obtained from adult or neonatal mouse hearts, and from cell lysates obtained from HEK-293 cells expressing SCN5A alone or cells co-expressing SCN5A and Navβ3. (B and C) Cell ...
The location of co-expressed SCN5A and Navβ3 subunits was investigated in HEK-293 cells by immunocytochemistry and confocal microscopy. The SCN5A location was visualized by expressing an SCN5A-Flag construct and probing with a Flag antibody (green signal) (Figure 5D, b and f), and the Navβ3 subunit was probed using the native antibody (red signal) (Figure 5D, c and g). For Navβ3-WT (Figure 5D, top panels), both SCN5A and Navβ3-WT localized at the plasma membrane. However, Navβ3 -V54G caused a marked decrease in the cell surface signal for both SCN5A and Navβ3 (Figure 5D, bottom panels). These results suggest that Navβ3-V54G caused retention of the two subunits and accounted for the decrease in INa density in the presence of Navβ3-V54G.
Although HEK-293 cells are the standard heterologous cell line for the study of SCN5A, our observation that HEK-293 cells have endogenously expressing Navβ3 prompted us to also study the effects of the Navβ3 subunit on SCN5A in COS cells which we have showed lack the endogenous Navβ3 subunit. Representative INa traces from COS cells co-expressing SCN5A and one of the following plasmids: a blank vector control, Navβ3-WT, Navβ3-V54G, or both Navβ3-WT and Navβ3-V54G at 1 : 1 ratio (Figure 6A and Table 2). In these cells, Navβ3-WT caused an increase in INa density, non-significant compared with SCN5A alone, and Navβ3-V54G had a profound and significant suppressive effect on INa density. When Navβ3-WT was co-expressed with NaVβ3-V54G, the INa density was not significantly different from Navβ3-WT. Summary of the INa density in each group is shown (Figure 6B and Table 2). In addition, co-expression with SCN5A, Navβ1 and Navβ3-WT, or Navβ3-V54G had no significant additional effects on kinetics (Table 2). In COS cells co-expressing the Navβ1 and Navβ3-WT, the levels of INa density were similar than in the absence of Navβ1. However, for Navβ3-V54G, the presence of the Navβ1 ‘partially rescues’ the decrease in INa density (Figure 6A and B).
Navβ3-V54G reduced INa in COS cells. Equal amounts of blank vector, Navβ3-WT or Navβ3-V54G, and in some cells Navβ1-WT were co-transfected with SCN5A in COS cells for a total amount of 1.5 µg DNA. (A) Whole-cell ...
Kinetics of SCN5A + β1-WT and β3 in COS cells
This relatively new technique provided a tool to quantitatively measure cell surface expression of SCN5A by imaging living cells attached at the bottom of 35 mm tissue culture plates. Here, COS cells co-expressing SCN5A Flag-tagged and Navβ3 plasmids as in Figure 6A and B were subjected to live-cell western blot using the anti-Flag antibody, then the signal was detected by a secondary anti-mouse antibody labelled with an infrared dye (IRDye 800), and detected on an infrared imaging system (Odyssey). Figure 6C shows the infrared signal at 800 nm wave length, and each plate has a confluent layer of COS cells with good transfection efficiency as indicated by GFP expression. A non-transfected plate was used to subtract the background from each plate containing cells expressing the SCN5A and the Navβ3 constructs. The infrared imaging analysis software quantifies the infrared signal (pixels count) within a pre-defined area (mm2), and Figure 6C shows the relative mean infrared signal intensities. The live-cell western technique is consistent with and corroborates the loss-of-function/trafficking-defective findings from the whole cell patch clamp and immunocytochemical analyses.
The patient described in this report had documented spontaneous ventricular fibrillation in the absence of structural heart disease or other well-defined electrophysiological diseases such as LQTS, BrS, or ARVC/D. IVF cases are often recognized and studied only after their first out-of-hospital cardiac arrest. A lack of specific electrocardiographic markers makes identification of pre-disposed individuals challenging. The ECG is often normal or does not provide sufficiently specific findings for clinical diagnosis in asymptomatic cases at risk of ventricular fibrillation.8,9 The patient's only electrocardiographic/structural peculiarity was the manifest epsilon wave in the right precordial leads of V1, V2, and V3 (Figure 1). The epsilon wave has been described in ARVC/D; however, our patient lacked other ECG findings often described in ARVC/D, such as T-wave inversion in anterior precordial leads, ventricular conduction delay, ventricular axis deviation, ectopy on Holter, and late potentials.10,11 Moreover, no structural or haemodynamic abnormalities were found by either echocardiography or CT scan. This case was diagnosed clinically as IVF and did not meet criteria for AVRC/D, but the implications of these findings may require reinterpretation should additional cases be found that more resemble AVRC/D.
Interestingly, his mother is an asymptomatic gene-mutation carrier and exhibited J-point elevation in her ECG. This early repolarization pattern previously thought to be a normal variant, may be a marker of life-threatening ventricular arrhythmias8 present in 31% of IVF, and J-point elevation was also a frequent observation in patients with IVF.9 These patterns, however, are also frequently observed in ‘normal’ subjects, as many as 7% of young athletes,12 and it is therefore a very non-specific marker for IVF predisposition. A possible overlap of BrS and IVF and association with early repolarization extends to the molecular level, where mutations in SCN5A that cause loss of function of INa have been associated with both IVF2,13 as well as BrS, and also electrogenesis of the early repolarization pattern.14 Our finding that Navβ3-V54G causes loss-of-function INa provides a plausible mechanism for IVF consistent with a molecular phenotype of loss of INa function previously associated with IVF, BrS, and early repolarization.14
The α subunit of the voltage-dependent Na channel associates with four smaller Navβ subunits (Navβ1, Navβ2, Navβ3, and Navβ4), which play critical roles in cell adhesion, signal transduction, channel expression at the plasma membrane, and voltage dependence of the channel gating. The Navβ subunits have been implicated previously in arrhythmia syndromes: altered interaction between the Navβ1 subunit and a mutated α subunit has been proposed as a mechanism for BrS,15 and mutations in the Navβ1 subunit itself have been described recently in BrS and conduction disease.16 Mutations in the Navβ4 subunit have been found in LQTS.17 Previous to this report, mutations in Navβ2 and Navβ3 have not been implicated in human arrhythmia, but interestingly, a transgenic mouse lacking the Navβ3 subunit exhibited susceptibility to ventricular arrhythmias18 and altered conduction19 very similar to that of a transgenic mouse model with decreased INa,20 and a mutation in SCN3B has been reported in a patient with an ECG pattern consistent with BrS.21
Navβ3 is expressed in ventricles and Purkinje cells22 and share 57 and 47% homology with Navβ1 and Navβ2, respectively. The co-IP data of the Navβ3 subunit and SCN5A (Figure 5) in both heterologous systems and native tissue support a direct or indirect physical association in addition to the functional effects (Figures 3 and 44). The reported effects of the Navβ3 subunit on INa vary depending upon the cell preparation (oocytes vs. somatic cells) and the sodium channel isoform used. We observed a hyperpolarizing effect on Nav1.5 inactivation in HEK-293 cells, which agrees with the Navβ3-mediated shift reported in INa from rat brain cells,23 Nav1.3 channels in CHO cells,24 Nav1.2 and Nav1.8 in oocytes (but no shift with Nav1.4),25 and on Nav1.5 in CHO cells.26 In contrast to our results, one study showed a depolarizing shift with Nav1.5 in oocytes.22 Navβ3 knockout mouse18 ventricular myocytes showed a hyperpolarizing shift in the knockout, suggesting that in the mouse heart in vivo, the effect of Navβ3 is also a depolarizing shift. In the knockout, however, levels of the Navβ1 subunit and the α subunit were measured and altered, and other unexamined secondary changes could have been present, so the pure effect of Navβ3 might differ from the results observed in the knockout mouse. Although altered kinetics is potentially important for function, the more dramatic effect observed by the Navβ3 subunit was an increase in INa density that was also observed with co-expression of SCN5A in oocytes,22 and consistent with the decrease in INa observed in myocytes of the Navβ3 knockout mouse.18
The Navβ3-V54G mutation reduced INa by >70% in HEK-293 cells (Figure 3) and by >90% in COS cells (Figure 6) compared with Navβ3-WT. Also, Navβ3-V54G did not cause the hyperpolarizing shift in inactivation induced by Navβ3-WT (Figure 4B). Both of these are consistent with a loss of the Navβ3-WT functional effects on INa. Fluorescent immunocytochemistry (Figure 5D) suggests that the mechanism for the decreased INa is a decreased expression of both the Navβ3 subunit and SCN5A at the cell surface. The detailed mechanisms for the effect, however, remained unclear. We discovered that HEK-293 cells express the Navβ3 subunit endogenously, whereas COS cells do not. This could account for the finding that overexpression of Navβ3-WT showed a non-significant increase in INa in HEK-293 cells. However, in COS cells, Navβ3-WT showed a non-significant trend for increased INa (Figures 3 and 66), consistent with endogenous Navβ3-WT effects in HEK-293 cells.
The patient was heterozygous for the mutation. We attempted to recapitulate this in vitro by co-expression of Navβ3-V54G with Navβ3-WT in COS cells. Here, we obtained a more highly variable reduction in INa density that did not reach significance, and we speculate that gene dosage may account for this discrepancy (data not shown). In addition, the effects in vivo may depend upon specific interactions with other subunits such as the Navβ1 subunit,26,27 although our co-expression studies with Navβ1 (Figure 6 and Table 2) suggest little effect on the Navβ3-WT, but a ‘partial rescue’ for the Navβ3-V54G. The extracellular domain of the Navβ3 exerted an important influence on channel kinetics, and the intracellular domain was important for targeting the channel to the surface membrane in one study.28 But, Navβ3-V54G in the extracellular domain had a profound effect on trafficking in our study, and this is consistent with a mutation Navβ3-L10P in the extracellular domain associated with loss of INa density in a BrS patient.21 The overall findings in vitro, however, are consistent with Navβ3-V54G being an ineffective chaperone for SCN5A compared with Navβ3-WT, and even competing with Navβ3-WT for this function. More insight into detailed mechanisms awaits further study.
The clinical findings and the functional data reported here support the idea that the SCN3B-encoded Navβ3 subunit interacts with SCN5A α subunits creating a loss-of-function phenotype, and supports SCN3B as a novel IVF-susceptibility gene. The Navβ3-V54G mutation caused loss of the Navβ3 function and a reduction in INa, possibly by interfering with the chaperone and cell membrane localization functions of the Navβ3 subunit. The pedigree was not sufficient for genetic linkage analysis; therefore, the pathogenicity of this mutation rests upon its (i) absence in 800 reference alleles, (ii) involvement of a highly conserved residue, and (iii) a markedly perturbed molecular/cellular phenotype that yields the loss of function of INa, providing a plausible arrhythmogenic mechanism consistent with previously described IVF and BrS mutations. In addition, at this time, the finding is from a single case, and it will be interesting to determine whether mutations in SCN3B explain other cases of IVF, genotype-negative BrS, or autopsy-negative sudden unexplained death.
Conflict of interest: M.J.A. is a consultant for PGxHealth. Intellectual property derived from M.J.A.'s research program resulted in license agreements in 2004 between Mayo Clinic Health Solutions (formerly Mayo Medical Ventures) and PGxHealth (formerly Genaissance Pharmaceuticals).
This work was supported by the University of Wisconsin Cellular and Molecular Arrhythmia Research Program (J.C.M.) and the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (M.J.A.), the Established Investigator Award from the American Heart Association (M.J.A.), and the National Institutes of Health HD42569 (M.J.A.) and HL71092 (J.C.M.).